- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Large Cap High Growth Potential
Global Pharmaceuticals & Biotech Large Cap High Growth Potential
UPDATED May 11, 2024
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
50 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | ||
603392 | CN¥66.30 | -2.9% | -5.5% | CN¥84.1b | CN¥70.40 | PE654.5x | E63.0% | 0.5% | ||
ALNY | US$150.47 | -1.2% | -26.7% | US$19.0b | US$220.38 | PS9.5x | E64.2% | n/a | ||
SRPT | US$131.82 | -1.4% | 9.7% | US$12.5b | US$165.89 | PE737.4x | E37.0% | n/a | ||
NBIX | US$136.70 | -2.8% | 41.4% | US$13.8b | US$157.81 | PE37.2x | E26.3% | n/a | ||
KRTX | US$329.83 | 3.3% | 80.7% | US$12.6b | US$326.92 | PS19238.9x | E60.1% | n/a | ||
ARGX | €347.90 | -3.0% | -6.0% | €20.7b | €437.12 | PS15.3x | E59.5% | n/a | ||
LLY | US$760.00 | 3.4% | 74.9% | US$684.3b | US$850.41 | PE111.5x | E27.3% | 0.7% | ||
500420 | ₹2,601.45 | -4.8% | 57.6% | ₹880.4b | ₹2,728.79 | PE58.9x | E21.3% | 1.2% | ||
MRNA | US$117.31 | -6.2% | -9.3% | US$45.0b | US$139.35 | PS8.7x | E68.8% | n/a | ||
SDZ | CHF32.55 | 5.0% | n/a | CHF14.0b | CHF35.25 | PE200.4x | E29.3% | 1.4% | ||
AZN | UK£123.70 | 2.7% | 3.0% | UK£191.8b | UK£133.20 | PE37.9x | E15.9% | 2.0% | ||
DIM | €205.70 | -1.2% | -16.5% | €20.0b | €251.33 | PE78.6x | E23.3% | 0.3% | ||
MRK | US$130.06 | 2.0% | 11.0% | US$329.4b | US$141.64 | PE142.9x | E24.9% | 2.4% | ||
ABBV | US$160.75 | -1.9% | 9.2% | US$283.9b | US$181.55 | PE47.7x | E23.2% | 3.9% | ||
MANKIND | ₹2,236.75 | -3.4% | 60.4% | ₹896.0b | ₹2,186.42 | PE51.9x | E18.7% | n/a | ||
ERF | €57.66 | 1.7% | -3.9% | €11.1b | €60.88 | PE43.4x | E20.2% | 0.9% | ||
DIVISLAB | ₹3,793.50 | -4.0% | 14.4% | ₹1.0t | ₹3,442.36 | PE72.8x | E24.1% | 0.8% | ||
GMAB | kr.2,003.00 | -2.8% | -30.2% | kr.129.4b | kr.2,469.88 | PE23.7x | E20.4% | n/a | ||
UCB | €123.00 | 2.1% | 44.3% | €23.3b | €125.49 | PE68x | E26.3% | 1.1% | ||
BMY | US$44.94 | 2.2% | -34.0% | US$91.1b | US$53.19 | PS2x | E43.8% | 5.3% | ||
A068270 | ₩192,900.00 | 2.1% | 15.8% | ₩39.8t | ₩230,117.65 | PE74.2x | E40.0% | 0.3% | ||
LONN | CHF526.20 | 1.3% | -8.4% | CHF37.9b | CHF573.86 | PE58x | E20.2% | 0.8% | ||
BGNE | US$161.13 | -0.7% | -32.4% | US$16.9b | US$266.66 | PS6.1x | E61.5% | n/a |